INTRODUCTION

Ranibizumab (brand names Byooviz, Cimerli, Lucentis, Susvimo) is a monoclonal antibody fragment (Fab) that targets vascular endothelial growth factor A (VEGF-A). Ranibizumab is used to treat various ocular disorders with abnormal growth of blood vessels, such as neovascular (wet) age-related macular degeneration.

This plasmid is designed for expressing Ranibizumab in mammalian expression system such as HEK293 or Chinese hamster ovary (CHO) cell line.

PRODUCT INFORMATION

Item No.: PPBD-155
Shipping: Lyophilized plasmid, or liquid plasmid, or plasmids on filter paper
Storage: -20 °C or 4°C according to instruction
Plasmid Backbone: Expression plasmid, flexible options, custom available
Quality Control: Sequencing validation

DRUG INFORMATION

Generic Name: Ranibizumab
Brand Name(s): Byooviz, Cimerli, Lucentis, Susvimo
Classification: Monoclonal antibody (mAb)
Target: VEGFA, MVCD1, VEGF, VPF, vascular endothelial growth factor A
Amino Acid Sequence: Identical to DB01270

PROTOCOL FOR PLASMID RECOVERY FROM FILTER PAPER

REFERENCE

[1] Gaudreault J, Fei D, Beyer JC, Ryan A, Rangell L, Shiu V, Damico LA. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina. 2007 Nov-Dec;27(9):1260-6.

[2] Kourlas H, Abrams P. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. Clin Ther. 2007 Sep;29(9):1850-61.

Contact Us